Literature DB >> 27286837

[Hyperuricemia and gout : New aspects of an old disease].

M Witt1, H Schulze-Koops2.   

Abstract

Gouty arthritis is one of the most common arthritides. Due to increasing life expectancy and changing life style, a rising incidence and prevalence of gout can be expected. Because of associations with the diseases metabolic syndrome and cardiovascular morbidity, gout patients often suffer from significant morbidity. Besides the consequent usage of conventional therapeutics, new treatments for gout attacks and for lowering urate levels are available even for patients refractory to conventional therapy.

Entities:  

Keywords:  Anakinra; Canakinumab; Computed X ray tomography, dual energy; Epidemiology, gout; Lesinurad

Mesh:

Substances:

Year:  2016        PMID: 27286837     DOI: 10.1007/s00108-016-0083-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Clinical image: Dual-energy computed tomographic molecular imaging of gout.

Authors:  Thorsten R C Johnson; Sabine Weckbach; Herbert Kellner; Maximilian F Reiser; Christoph R Becker
Journal:  Arthritis Rheum       Date:  2007-08

Review 2.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality.

Authors:  Chang-Fu Kuo; Lai-Chu See; Kuang-Hui Yu; I-Jun Chou; Meng-Jiun Chiou; Shue-Fen Luo
Journal:  Rheumatology (Oxford)       Date:  2012-08-25       Impact factor: 7.580

4.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

Review 6.  Imaging modalities for the classification of gout: systematic literature review and meta-analysis.

Authors:  Alexis Ogdie; William J Taylor; Mark Weatherall; Jaap Fransen; Tim L Jansen; Tuhina Neogi; H Ralph Schumacher; Nicola Dalbeth
Journal:  Ann Rheum Dis       Date:  2014-06-10       Impact factor: 19.103

7.  Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.

Authors:  Naomi Schlesinger; Eduardo Mysler; Hsiao-Yi Lin; Marc De Meulemeester; Jozef Rovensky; Udayasankar Arulmani; Alison Balfour; Gerhard Krammer; Peter Sallstig; Alexander So
Journal:  Ann Rheum Dis       Date:  2011-05-03       Impact factor: 19.103

8.  2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor
Journal:  Ann Rheum Dis       Date:  2015-10       Impact factor: 19.103

9.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.

Authors:  L Annemans; E Spaepen; M Gaskin; M Bonnemaire; V Malier; T Gilbert; G Nuki
Journal:  Ann Rheum Dis       Date:  2007-11-02       Impact factor: 19.103

10.  Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Authors:  Herbert S B Baraf; Michael A Becker; Sergio R Gutierrez-Urena; Edward L Treadwell; Janitzia Vazquez-Mellado; Claudia D Rehrig; Faith D Ottery; John S Sundy; Robert A Yood
Journal:  Arthritis Res Ther       Date:  2013-09-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.